http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Seismic response estimation of steel buildings with deep columns and PMRF
Alfredo Reyes-Salazar,Manuel E. Soto-López,José R. Gaxiola-Camacho,Edén Bojórquez,Arturo Lopez-Barraza 국제구조공학회 2014 Steel and Composite Structures, An International J Vol.17 No.4
The responses of steel buildings with perimeter moment resisting frames (PMRF) with medium size columns (W14) are estimated and compared with those of buildings with deep columns (W27), which are selected according to two criteria: equivalent resistance and equivalent weight. It is shown that buildings with W27 columns have no problems of lateral torsional, local or shear buckling in panel zone. Whether the response is larger for W14 or W27 columns, depends on the level of deformation, the response parameter and the structural modeling under consideration. Modeling buildings as two-dimensional structures result in an overestimation of the response. For multiple response parameters, the W14 columns produce larger responses for elastic behavior. The axial load on columns may be significantly larger for the buildings with W14 columns. The interstory displacements are always larger for W14 columns, particularly for equivalent weight and plane models, implying that using deep columns helps to reduce interstory displacements. This is particularly important for tall buildings where the design is usually controlled by the drift limit state. The interstory shears in interior gravity frames (GF) are significantly reduced when deep columns are used. This helps to counteract the no conservative effect that results in design practice, when lateral seismic loads are not considered in GF of steel buildings with PMRF. Thus, the behavior of steel buildings with deep columns, in general, may be superior to that of buildings with medium columns, using less weight and representing, therefore, a lower cost.
Belen Lopez-Millan,Rafael Diaz de la Guardia,Heleia Roca-Ho,Carmen M García-Herrero,Jessie R Lavoie,Michael Rosu-Myles,Elena Gonzalez-Rey,Francisco O’Valle,Gabriel Criado,Mario Delgado,Pablo Menendez 생화학분자생물학회 2017 Experimental and molecular medicine Vol.49 No.-
Thalidomide is an immunomodulatory drug (IMiD) with proven therapeutic action in several autoimmune/inflammatory diseases; however, its inherent high toxicity has led to the development of more powerful and safer thalidomide analogs, including lenalidomide and pomalidomide. These are new generation IMiDs that exhibit direct antitumor activity as well as anti-inflammatory/immunomodulatory properties, and are FDA-approved for the treatment of several hematological malignances. Here we investigated the potential therapeutic effects of lenalidomide and pomalidomide in several experimental murine models of autoimmune/inflammatory diseases: 2,4,6-trinitrobenzene sulfonic acid- and dextran sulfate sodium-induced inflammatory bowel disease and type II collagen-induced arthritis. Lenalidomide displayed a strong therapeutic effect in all these models of autoimmune/inflammatory diseases, while the effect of pomalidomide was less pronounced. In vitro experiments confirmed the immunosuppressive effect of both IMiDs on the proliferative response of stimulated human lymphocytes and on the balance of secreted cytokines toward an anti-inflammatory profile. We conclude that lenalidomide may offer a therapeutic opportunity against autoimmune/inflammatory diseases.